

CORPORATE PROFILE

Through cutting-edge science and medicine, Biogen Idec discovers, develops and delivers to patients worldwide innovative therapies for the treatment of neurodegenerative diseases, hemophilia and autoimmune disorders. Founded in 1978, Biogen Idec is the world's oldest independent biotechnology company. Patients worldwide benefit from its leading multiple sclerosis therapies and the company generates more than \$5 billion in annual revenues. For product labeling, press releases and additional information about the company, please visit www.biogenidec.com.

STOCK PERFORMANCE

BIIB (COMMON STOCK)

Exchange NASDAQ (US Dollar)
 Price **\$250.80**
 Change (%) ▼ 2.17 (0.86%)
 Volume 833,009
 52 Week Low \$205.43
 Market Cap \$53,574,962,522
 Rolling EPS 15.96
 PE Ratio 15.7143
 Shares Outstanding 213,616,278
 Data as of 05/26/17 4:00 p.m. ET



RECENT PRESS RELEASES

- 05/24/17
Biogen's FAMPYRA® Granted Standard Marketing Authorization in European Union for Improvement of Walking in People with MS
- 05/17/17
Biogen to Present at the Bernstein 33rd Annual Strategic Decisions Conference
- 05/15/17
Biogen Acquires Remedy Pharmaceuticals' CIRARA™ for Large Hemispheric Stroke
- 04/24/17
TECFIDERA® and TYSABRI® Data Demonstrate Improved Outcomes with Early MS Treatment
- 04/24/17
Final Phase 3 Study Data Show SPINRAZA® (nusinersen) Significantly Improved Motor Function in Children with Later-Onset Spinal Muscular Atrophy

UPCOMING EVENTS

There are currently no events scheduled.

RECENT SEC FILINGS

FILING DATE	FORM
05/04/17	4
05/02/17	4
05/01/17	4
04/27/17	4
04/26/17	DEFA14A

ANALYST ESTIMATES / RATINGS

Mean Recommendation: 2.2



Sell

Strong Buy

EPS TREND

		Current	30 Days Ago	90 Days Ago
QTR	Jun 17	4.54	5.22	5.19
QTR	Sep 17	5.35	5.33	5.34
QTR	Dec 17	5.40	5.43	5.46
QTR	Mar 18	5.34	5.33	5.32
F Y	Dec 17	20.48	20.96	20.98
F Y	Dec 18	22.57	22.38	22.52

OWNERSHIP SUMMARY

	Holders	Value (\$MM)	% O/S	Shares
Institution	1,453	52,725.13	90.9	192,701,903
Mutual Fund	2,594	31,123.29	52.8	111,995,417
Insider *	22	79.61	0.1	289,749

**Insider values reflect direct beneficial ownership.*

	Shares Held	% O/S	Share Change	Filing Date
PRIMECAP Management Company	15,477,424	7.3	-106,963	03/31/17
The Vanguard Group, Inc.	14,352,490	6.8	342,568	03/31/17
BlackRock Institutional Trust Company, N.A.	11,705,223	5.5	304,532	03/31/17
State Street Global Advisors (US)	9,580,383	4.5	219,502	03/31/17
ClearBridge Investments, LLC	9,121,025	4.3	351,224	03/31/17
T. Rowe Price Associates, Inc.	8,118,191	3.8	-600,042	03/31/17
Wellington Management Company, LLP	5,712,355	2.7	-131,919	03/31/17
Fidelity Management & Research Company	5,393,494	2.5	-2,442,595	03/31/17
AllianceBernstein L.P.	2,937,319	1.4	294,308	03/31/17
Sands Capital Management, LLC	2,475,937	1.2	-102,972	03/31/17

Powered By **EDGAR**Online

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Minimum 20 minutes delayed